Welcome to our dedicated page for Arrowhead Pharma SEC filings (Ticker: ARWR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Arrowhead Pharmaceuticals filings document regulatory disclosures for a commercial-stage RNAi therapeutics company with common stock registered on the Nasdaq Global Select Market. Form 8-K reports furnish fiscal results, Regulation FD clinical-data presentations, material agreements and capital-structure updates, including disclosures tied to convertible senior notes.
Proxy and annual-meeting filings cover board elections, executive-compensation votes, incentive-plan approvals and auditor ratification. The filing record also documents securityholder voting outcomes, governance matters, and disclosures related to programs such as REDEMPLO, ARO-INHBE and ARO-ALK7, alongside the company’s RNAi platform, development pipeline and commercial activities.